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Protein scaffolds can provide a promising alternative to antibodies for various biomedical
and biotechnological applications, including therapeutics. Here we describe the design
and development of the Alphabody, a protein scaffold featuring a single-chain antiparallel
triple-helix coiled-coil fold. We report afﬁnity-matured Alphabodies with favourable
physicochemical properties that can speciﬁcally neutralize human interleukin (IL)-23, a
pivotal therapeutic target in autoimmune inﬂammatory diseases such as psoriasis and
multiple sclerosis. The crystal structure of human IL-23 in complex with an afﬁnity-matured
Alphabody reveals how the variable interhelical groove of the scaffold uniquely targets a large
epitope on the p19 subunit of IL-23 to harness fully the hydrophobic and hydrogen-bonding
potential of tryptophan and tyrosine residues contributed by p19 and the Alphabody,
respectively. Thus, Alphabodies are suitable for targeting protein–protein interfaces of
therapeutic importance and can be tailored to interrogate desired design and binding-mode
principles via efﬁcient selection and afﬁnity-maturation strategies.
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I
n the post-genomic era, the application and engineering of
therapeutic antibodies to tackle cancer, as well as autoimmune
and inﬂammatory disorders, has brought about a pronounced
paradigm shift in the therapeutic targeting of protein–protein
interactions1,2. At the same time, the elucidation of the molecular
and structural basis of protein–protein interactions has emerged
as the cornerstone for understanding the extra- and intra-cellular
context of signalling pathways and for the rational design of
molecules with antagonistic or agonistic behaviour against
molecular targets of biomedical importance3. The inherent
challenges associated with targeting protein–protein interfaces
in a therapeutic setting4 have stimulated considerable efforts
towards designed protein interactions5 and the development of
engineered protein scaffolds that could serve as alternatives to
antibodies in biomedical applications6,7. For instance, non-
antibody molecular-binding platforms such as the DARPins8
Monobodies9, Anticalins10, Afﬁbodies11, Afﬁtins12 and the
Adnectins13 have led to a large expansion of the structural
repertoire of engineered protein scaffolds and have contributed
signiﬁcant added value in terms of their diverse physicochemical
properties, pharmacokinetics and delivery to and through tissues
of interest6.
The Alphabody scaffold is a computationally designed protein
scaffold of about 10 kDa molecular weight, which was developed
to serve as a therapeutic agent14. The scaffold does not have a
counterpart in nature and is composed of a single contiguous
polypeptide chain designed to adopt a triple-helix coiled-coil
fold14. To explore the potential of the Alphabody platform in
targeting biomedically relevant protein–protein interactions, we
opted to target the pro-inﬂammatory cytokine interleukin (IL)-23,
a well-established therapeutic target for the treatment of
inﬂammatory diseases15. IL-23 is produced by dendritic cells
and macrophages and is required for the survival and expansion of
pro-inﬂammatory Th17 cells, which by virtue of their production
of IL-17 are associated with the pathogenesis of autoimmune
inﬂammatory disorders, such as multiple sclerosis, rheumatoid
arthritis, psoriasis and inﬂammatory bowel disease15–18. In
addition, IL-23 deﬁciency was recently shown to protect mice
from tumour formation underscoring the general role of IL-23 in
suppressing natural or cytokine-induced innate immunity and in
promoting tumour development and metastasis19–21.
IL-23 adopts an atypical heterodimeric structure consisting of a
p40 subunit encompassing three ﬁbronectin-III-like domains,
which is linked via a disulﬁde bond to an a-helical bundle subunit
(p19) that topologically resembles long-chain helical cytokines22–24.
IL-12, also a heterodimeric cytokine secreted by the dendritic cell to
promote development of Th1 cells, also features the p40 subunit
but the latter is coupled to a p35 subunit instead15. While both
cytokines employ their p40 subunits to bind to IL-12Rb1 as a
common receptor, IL-23 uses its p19 subunit to engage its cognate
IL-23R, whereas IL-12 binds to IL-12Rb2 via the p35 subunit.
Interestingly, the monoclonal antibody Ustekinumab, originally
developed to neutralize IL-12 for the treatment of autoimmune
inﬂammatory disorders, was subsequently shown to also
antagonize IL-23 due to its ability to bind to the common p40
subunit employed by the two cytokines25–29. One of the reported
side effects of the currently available anti-IL-12/IL-23 p40
therapeutic options is an increased susceptibility to infections,
related to the important role IL-12 in mounting an appropriate
immune system protection against pathogens21. In addition, several
reports have described the protective role of and therapeutic
potential of IL-12 in tumour development20,30,31.
We here report the design and development of Alphabodies as
protein scaffolds not found in nature bearing unique physico-
chemical and structure–function properties, and probe their
potential to serve as antagonists against pro-inﬂammatory human
IL-23. We show that afﬁnity-matured Alphabodies can bind with
ultra-high afﬁnity to IL-23, but not IL-12, via an extensive
interaction interface that engages the p19 subunit of IL-23 to
abrogate IL-23-mediated signalling in vitro and in vivo. Together,
these ﬁndings establish the Alphabody as a potent and versatile
protein-based scaffold and set the stage for their application in
disrupting diverse protein–protein interactions of therapeutic
relevance.
Results
Design and development of a reference Alphabody scaffold.
Our endeavours towards the design of the Alphabody scaffold
originated from the wealth of information on diverse types of
coiled-coils32, as recorded in the CCþ database33. Initially, the
Alphabody scaffold was launched as an assembly of three non-
covalently associated peptides designed to form a parallel coiled-
coil trimer34. This design was then redeﬁned as a three-helix
coiled-coil scaffold, wherein all three helices are contained within
a single contiguous polypeptide chain. The rationale behind this
effort has been manifold. First, the folding of a single-chain
polypeptide, as opposed to peptidic associations, is not dependent
on the concentration. Second, the designed scaffold needed to be
producible by cost-effective and scalable recombinant protein
production methods. Third, a single-chain construct allows
independent deﬁnition of each amino-acid residue in any
a-helix of the sequence. Fourth, a stable and autonomously
folded protein can, in principle, allow accommodation of both
conformational and linear binding epitopes.
The reference scaffold, hereafter referred to as ‘scRef_L16’, was
designed to feature three a-helices composed of four heptad
repeats each, connected via glycine/serine-rich linkers (Fig. 1a).
The reference sequence of each heptad repeat was deﬁned as
‘IaAbAcIdQeKfQg’. Isoleucines were chosen at the heptad core
positions (a and d) because of their speciﬁcity to induce three-
stranded coiled-coil structures. Electrochemically neutral yet
polar glutamines were placed at the interhelical ‘groove’ positions
(e and g). Alanines were chosen at the exposed b- and c-positions
because of their high a-helical propensity. Positively charged
lysine was chosen at the most exposed f-position. Minor
deviations from this heptad motif were introduced near the
helical termini to improve capping. The full amino-acid sequence
of scRef_L16 can be written as N-HRS1-L1-HRS2-L2-HRS3-C,
wherein heptad repeat sequences HRSx have the sequence
IEEIQKQIAAIQKQIAAIQKQIYRM and linker sequences Lx
are TGGSGGGSGGGSGGGSGMS (the capping residues ‘T’ and
‘MS’ at the N- and C termini are formally included in the linker
segments).
Isoleucine core residues are known to have a high tendency to
induce parallel coiled-coil trimers35. However, molecular
modelling using the parallel Ile-stabilized trimer GCN4-pII
(PDB code 1GCM)35 and the antiparallel Leu-stabilized coiled
serine (PDB code 1COS)36 suggested that core residue layers with
Ile at the a- and d-positions in two parallel helices could also be
complemented by Ile core residues in a third, antiparallel helix
(Fig. 1b,c). The linkers in scRef_L16 were therefore chosen to be
long enough to allow antiparallel, as well as parallel folding (16
residues can theoretically bridge about 16 3Å¼ 48Å, while 7
helical turns are 7 5.4 Å¼ 38Å in height). To explore the actual
folding preferences in this regard, scRef_L16 and different
variants were produced in soluble form and physicochemically
characterized.
His-tagged scRef_L16 and other variants described below were
puriﬁed from Escherichia coli using metal-afﬁnity and size-
exclusion chromatography (SEC), with yields reaching several
milligrams of pure protein per liter of culture. Circular dichroism
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measurements showed that scRef_L16 adopted a predominantly
a-helical structure that was remarkably stable (Tm value of
B120 C), as revealed by thermal denaturation studies in the
presence of guanidine hydrochloride (Fig. 2a–c). Subsequently, a
variant referred to as ‘scRef_L8’ was produced in which both
linker segments were shortened by 8 amino-acid residues. Such
linkers would be physically too short to connect the helical
termini in a fully parallel coiled-coil structure. Surprisingly, we
found that scRef_L8 and scRef_L16 were equally thermo-
stable (Fig. 2b). This ﬁnding suggested that both constructs
adopt an antiparallel conﬁguration. However, it remained
possible that an unfavourably short linker could induce local
unwinding near the termini without causing an energetic cost in
stability.
To examine the local unwinding hypothesis, a panel of variants
was produced based on a scaffold variant carrying one fewer
heptad repeat (referred to as ‘scShort’), equipped with linkers
composed of 6–18 Gly/Ser residues (L6–L18). Consistent with the
loss of two heptad core layers per construct, all scShort variants
generally showed Tm values that were about 40 C lower than the
longer scRef constructs at comparable concentrations of GuHCl
(Fig. 2b). The absence of any signiﬁcant effect of the linker length
in the context of a scaffold stabilized by only six core layers
invalidated the local unwinding hypothesis and strengthened the
notion of an antiparallel fold in an ‘up-down-up’ conﬁguration.
Design of Alphabody libraries. To explore the potential of
scRef_L16 for generating target-speciﬁc binders, three random
libraries were designed (Fig. 1a). A ﬁrst library, denoted ‘scLi-
b_AC11’, comprised six randomized c- and g-positions in helix A
and ﬁve randomized b- and e-positions in helix C. These
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Figure 2 | Stability and folding of the Alphabody scaffold. (a) Stability of the scRef_L16 reference Alphabody revealed by circular dichroism thermal
denaturation experiments performed in 3–6M guanidine hydrochloride (GuHCl). (b) Melting temperatures from thermal denaturation experiments
as a function of GuHCl concentration. Alphabody scRef_L16 was tested together with scRef_L8, and compared with Alphabody scShort having four different
linker lengths (L6–L18). (c) Circular dichroism wavelength scan on puriﬁed scRef_L16 conﬁrming the correct folding and alpha-helical nature of the
scaffold in its puriﬁed form.
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Figure 1 | Schematic overview of the Alphabody platform. (a) Alphabodies are encoded by a single polypeptide featuring three a-helices (A–C)
connected by linkers (L1, L2). The sequences of the three generic libraries (scLib_AC11, scLib_C9 and scLib_AC7) as well as the maturation library (matLib)
used for biopanning are depicted. Amino-acid positions denoted with ‘x’ mark positions that were fully or partially randomized. The N terminus (N) of the
Alphabody consists of the ﬁrst 21 amino acids from the pelB leader sequence followed by an Asp in scLib_AC7 or Ser in all other cases. The linkers
connecting the helices (L1 and L2) are identical within each library (La¼T (GGSG)4MS, Lb¼T(GGSG)4MD). The C terminus (C) differed between the
generic libraries (TPGGSGGAAAHHHHHHGRAQ) and the maturation library (AAAHHHHHHQ) where in the latter the glutamine residue was encoded by
an amber stop codon allowing for the translation of PIII fusion proteins. The sequence numbering corresponds to the maturation library, matLib.
(b) Schematic rendering of the Alphabody scaffold as a single-chain three-helix antiparallel coiled-coil. (c) Schematic representation of the interactions
between the core residues in an antiparallel coiled-coil. Hydrophobic interactions between isoleucines at positions a and d in each heptad repeat
stabilize the Alphabody fold. Additional stabilizing interactions can arise from amino acids at positions e and g in helices A and C, positions g and g in
helices B and C and positions e and e in helices A and B.
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positions form a contiguous surface contributed by 11/14 (79%)
of all b-, c-, e- and g-positions of the groove surface in between
helices A and C (Fig. 1a–c). On the basis of the same design
principle applied to the scShort sequence, the ‘scLib_AC7’ library
was generated displaying four randomized positions in helix A
and three in helix C. Both of these libraries are further referred to
as ‘groove libraries’. A third library, ‘scLib_C9’, was derived from
scRef_L16 and was intended to explore the surface functionality
of helix C. Therefore, nine randomizations were introduced at b-,
c- and f-positions in helix C. This library is further referred to as a
‘helix surface library’.
Identiﬁcation of Alphabody binders to human IL-23. The initial
biopanning campaign employed the aforementioned generic
libraries displayed as fusion constructs to the pIII protein of M13
phage. The library sizes ranged from 1.0 to 1.7 108 unique clones.
Enzyme-linked immunosorbent assay (ELISA) screening of output
clones from consecutive biopanning rounds showed gradual
enrichment of positive clones (optical densities (ODs) in screening
ELISA at least three times higher than background), from about
33% in round 3 up to 95% in round 5 (Supplementary Fig. 1).
Next, 91 positive clones from selection rounds 3, 4 and 5 were
sequenced. We found that all binding clones originated from the
groove libraries (scLib_AC11: 80 clones, scLib_AC7: 11 clones and
scLib_B9: 0 clones). The population comprised 36 unique
sequences, with some convergence (duplicates) already seen in
round 3 and gradually increasing in the next rounds. Strikingly, the
majority of sequences (56%) showed severe deletions primarily in
helix B, with 5 clones (3 unique) lacking 2 heptad repeats, 35 clones
(12 unique) lacking the entire helix B and 5 clones (3 unique)
comprising only helix C. In addition, a marked enrichment in
proline and amber stop codons was observed in the helix A,
especially among clones lacking deletions in the sequence. The
observed deﬁciencies in the sequences are likely due to the usage of
the PelB signal sequence, which mediates post-translational
translocation of protein to the bacterial periplasm through the Sec
pathway. However, this signal sequence was previously shown to
be inefﬁcient for the display of fast-folding proteins37, as we have
now also observed in the case of Alphabodies. Evidently, while
defective sequences may be true binders as polypeptides with or
without tertiary structure, their inherent instability renders them
less-well controllable in terms of structural and physicochemical
properties, and thus not well suited for further development. We
have now resolved this issue in current work by substituting the
PelB signal sequence with the DsbA signal sequence, which directs
protein translocation to the periplasm via the co-translational
signal recognition particle (SRP) pathway38,39.
Supplementary Table 1 shows the top-10 unique clones
without B-helix deletions ranked according to binding perfor-
mance in phage ELISA, the degree of competition by the
neutralizing monoclonal antibody B-Z23 directed against the p19
subunit of IL-23 and the amino-acid residues observed at the
variable positions. Apart from the Pro and stop codon
enrichments, clone 72 had three helix-destabilizing glycines in
helix A. In contrast, four clones showing nearly complete
inhibition of binding to IL-23 in the presence of the neutralizing
antibody B-Z23 (clones 52, 44, 59 and 33) were less affected by
destabilizing elements (only clone 44 had a Pro at position 1 g).
Further sequence comparisons elucidated the following apparent
consensus binding motif: position A2g: aliphatic (M/I/V); A3c:
small (A/G/S); A3g: aromatic (W/Y); C3b: aliphatic (V/I/L); C3e:
aromatic (F/Y).
Development of afﬁnity-matured Alphabodies against IL-23.
Clone 59 (hereafter referred to as ‘Cl59’) was puriﬁed as a soluble
Alphabody following expression in E. coli and was subsequently
tested in various binding and functional assays. We found that
Cl59 bound with high afﬁnity to human IL-23 (KD¼ 3.8 nM in
equilibrium ELISA and KD¼ 7.0 nM in a kinetic ELISA assay). As
described below, it also displayed moderate antagonistic activity
in a functional assay on mouse splenocytes (KI¼ 69 nM)
(Table 1). In light of its promising initial characteristics, Cl59 was
selected as the starting point for afﬁnity maturation.
A maturation library termed ‘matLib’ (Fig. 1a; Supplementary
Table 2) was established based on the sequence of Cl59 and the
apparent consensus binding motif (Supplementary Table 1). This
library was used to conduct two afﬁnity-maturation campaigns in
parallel. This resulted in a large panel of variants with improved
apparent afﬁnities in phage format, from which 14 unique clones
were selected for further characterization in soluble format. To
this set we added two consensus sequences from each campaign
(‘MAcons’ and ‘MBcons’), three computationally designed
variants (‘Cl59m’, ‘59m_C2eQ’ and ‘59m_A3cA_A4cS_C2eQ’)
and the reference variant Cl59. Supplementary Table 3 lists the
names and constitution of these 20 Alphabody variants in terms
of selected residues at the variable positions, linker lengths and
B-helix modiﬁcation. All constructs were puriﬁed from E. coli
with yields ranging from 0.37 to 10.1mg per liter culture
(mean¼ 2.7mg l 1).
We employed a broad set of binding assays to characterize this
set of 20 Alphabodies, which revealed that the vast majority of
maturation clones (# 1–14) displayed subnanomolar afﬁnities to
IL-23 (Table 1). Both maturation campaigns yielded high-afﬁnity
binders (Fig. 3a). The highest afﬁnity in standard ELISA assays
was measured for MA12 and MA5 (KD¼ 0.1 nM), which is a
factor 38 better than the non-matured variant Cl59. Kinetic
ELISA assays (Supplementary Fig. 2) and standard ELISA data
(Fig. 3a) were globally in good agreement, as inferred from the
consistency between sub- and supra-nanomolar afﬁnities
(Table 1). The main improvement in afﬁnities appears to have
arisen from an increase in the kon by about one order of
magnitude, with some kon values exceeding 106M 1 s 1
(Table 1). Furthermore, KD values measured via phage-coated
ELISA were generally in good agreement with KD values obtained
for the soluble constructs, indicating that afﬁnities determined in
the early-screening phase of phage display are good predictors of
the afﬁnities of the soluble constructs.
Antagonistic potency of afﬁnity-matured Alphabodies. To
assess the antagonistic capacity of the selected Alphabodies
in vitro, a mouse splenocyte assay was established40. Functional
inhibition constants (KI) were determined by measuring the
inhibition of IL-23-induced IL-17 production in murine
splenocytes. We observed that the majority of subnanomolar
afﬁnity binders also inhibited IL-23 with subnanomolar functional
inhibition constants (Table 1). Over the whole range, the majority
of KI values deviated by less than a factor 3 from the binding KD
(median KI/KD¼ 2.7) (Fig. 3b). Alphabody Cl59, which had the
lowest afﬁnity, also showed the weakest inhibition. The second
best binder, MA12, showed the strongest inhibition capacity
(KI¼ 0.13 nM). This suggests that the functional inhibition
potencies are predominantly determined by the binding
afﬁnities. In addition, we sought to characterize the speciﬁcity of
binding of matured Alphabodies against human IL-23 compared
with IL-12 by ELISA, as this could have therapeutic implications
in targeting the functional dichotomy between these two pro-
inﬂammatory cytokines. We found that both representative
Alphabodies tested, MA12 and MB23, exhibited exquisite
speciﬁcity towards IL-23 (Fig. 3c) suggesting that matured
Alphabodies only target unique structural features in IL-23.
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To conﬁrm the binding and inhibition data in another cellular
assay, the top-performing Alphabodies were tested on their
capacity to neutralize IL-23-mediated signalling in a human DB
lymphoma cell line41. For all Alphabodies tested, a clear dose-
dependent inhibition of STAT3 phosphorylation was observed.
Functional inhibition constants were determined using a
calibration curve, in a similar manner as for the splenocyte
assay. Here, Alphabody MB23 performed best, with a KI of
0.16 nM, while most other variants were also found to have
subnanomolar inhibition constants (Table 1).
In addition, we attempted to investigate the in vivo efﬁcacy of
one of the best binders, MB23, in a mouse model for skin
inﬂammation induced by intradermal injection of human IL-23
into the ear42,43. In this model, repeat dosing with human IL-23
resulted in psoriasis-like thickening of the ear skin epidermis and
swelling of the ear, which could be monitored in vivo by calliper
measurements (Fig. 4). The negative-control group, which was
injected with phosphate-buffered saline (PBS) showed no
thickening, whereas the positive-control group injected with
IL-23 only (group A) showed gradual thickening as of day 8. Mice
in groups B and C were injected with both IL-23 and MB23,
which was PEGylated (40 kDa linear polyethylene glycol (PEG))
via a cysteine residue introduced in the B-helix of the Alphabody.
Group B received intradermal MB23 injections and Group C was
injected intraperitoneally. Indeed, both MB23-treated groups
showed the same ear-thickness curves, only slightly above the
negative-control curve, indicating that MB23 treatment effectively
suppressed IL-23-induced ear swelling (Fig. 4).
Structure of Alphabody MA12 and its complex with IL-23. To
obtain structural insights into the three-dimensional structure of
the Alphabody scaffold and the structural and binding principles
underlying its neutralizing interaction with IL-23, we carried out
crystallographic studies of human IL-23 in complex with MA12
complemented by isothermal titration calorimetry (ITC) and
surface plasmon resonance (SPR). Human IL-23 was transiently
expressed by co-transfecting IL-12 subunit beta (p40) and IL-23
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Table 1 | Binding characteristics of developed Alphabodies as determined via ELISA, kinetic ELISA, phage-coated ELISA,
splenocyte assays and cellular assays employing a DB cell line.
Clone no. Alphabody ELISA Kinetic ELISA Phage-coated
ELISA
Splenocyte assay DB assay
KD (nM) kon (M
 1 s 1) koff (s 1) KD (nM) KD (nM) KI (nM) KI (nM)
1 Cl59 3.80 1.0 105 7.0 104 7.00 3.00 69.0 ND
2 MA12 0.11 8.1 105 2.1 104 0.26 0.08 0.13 0.35
3 MB23 0.17 1.5 106 2.1 104 0.15 0.07 0.20 0.16
4 MB64 0.21 1.1 106 3.3 104 0.30 0.09 0.18 0.46
5 MA5 0.10 4.5 106 1.6 104 0.03 0.20 1.15 0.45
6 MA15 0.31 8.0 105 7.2 10 5 0.09 0.12 0.48 0.29
7 MB9 0.27 1.9 106 2.5 104 0.13 0.20 0.36 0.70
8 MA9 0.17 1.4 106 3.5 104 0.25 0.20 0.46 0.24
9 MB38 0.20 1.0 106 2.2 104 0.21 0.18 1.01 0.66
10 MB74 0.35 6.5 105 1.6 104 0.25 0.47 0.90 1.80
11 MB67 0.25 1.6 106 2.2 104 0.14 0.21 1.33 ND
12 MA14 1.80 2.0 105 5.0 104 2.50 1.50 11.0 ND
13 MA23 0.29 4.5 105 3.2 104 0.70 0.70 10.0 ND
14 MB43 0.20 1.3 106 1.4 104 0.11 0.18 0.88 ND
15 MB76 1.80 2.5 105 5.6 104 2.30 0.16 1.70 ND
16 MAcons 0.23 2.5 106 3.2 104 0.13 ND 4.10 ND
17 MBcons 2.80 2.2 105 5.9 104 2.70 ND 0.65 0.80
18 Cl59m ND ND ND ND ND 22.0 1.73
19 59m_C2eQ 0.93 1.1 105 4.3 104 3.90 ND 1.90 ND
20 59m_A3cA_A4cS_C2eQ 0.39 3.5 105 2.6 104 0.75 ND 0.70 ND
ELISA, enzyme-linked immunosorbent assay; ND, not determined.
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subunit alpha (p19) in HEK239T cells in the presence of kifu-
nensine to limit the extent of N-linked glycosylation44. N-linked
glycosylation on IL-23 was further trimmed during puriﬁcation
by treating IL-23 with EndoH. The free cysteine of the MA12
Alphabody was blocked by iodoacetamide and the N-terminal
His-tag was removed by trypsin. Mixing of puriﬁed human IL-23
with an excess of puriﬁed MA12, followed by SEC, yielded a
highly monodisperse fraction containing the IL-23:MA12
complex (Fig. 5a). ITC experiments showed that MA12 binds
to IL-23 with subnanomolar afﬁnity (KD¼ 0.35 nM) ), in what
emerged as an enthalpically driven interaction with a 1:1
stoichiometry (Fig. 5b). Such binding afﬁnity is consistent with
the ELISA-based afﬁnity determinations (Table 1). In addition,
kinetic binding parameters obtained by SPR indicated a relatively
fast on-rate (kon¼ 2.6 105M 1 s 1) and a slow off-rate
(koff¼ 1.2 10 4 s 1), yielding a KD¼ 0.46 nM, in good
agreement with values obtained from all other binding assays
employed (Fig. 5c; Table 1).
Crystallization trials of highly monodisperse preparations of
the IL-23:MA12 complex yielded two distinct crystal forms that
allowed us to determine crystal structures at 1.74 and 3.4 Å
resolution (Table 2), providing the opportunity to visualize the
binding epitope in detail and to cross-validate structural
observations. MA12 folds into a left-handed triple-helix coiled-
coil structure, with the binding surface located mainly at the
C-terminal half of helices A and C (Fig. 6a,b). The same structure
and binding mode to IL-23 are maintained in both crystal forms
(Supplementary Fig. 3). In agreement with the ITC-derived
stoichiometry of the complex, one copy of MA12 binds to the p19
subunit of IL-23 and is oriented parallel to the longitudinal axis of
the p40 subunit (Fig. 6a,b). The respective binding interfaces
feature 20 amino-acid residues contributed by MA12 and 28
amino-acid residues contributed by p19, burying a total surface
area of 800 and 840Å2, respectively (Fig. 6a; Supplementary
Table 4). This MA12 interface area constitutes 14.4% of the total
surface area of the Alphabody. Five hydrogen bonds and two salt
bridges are formed upon binding, while the rest of the interaction
interface can be described in terms of van der Waals contacts
(Supplementary Table 4).
The binding interface is further hallmarked at its two ends by
two prominent attachment points. At one end, Trp156 from
IL-23 p19, a residue that was previously proposed to deﬁne a
hotspot mediating the cognate interaction of IL-23 with IL-23R
(ref. 24), pokes the benzene ring part of its indole ring into the
groove deﬁned by helices A and C of the Alphabody, to interact
with the Ile106 core residue (Fig. 6d). At the same time, the N–H
group of the indole moiety engages in a water-mediated hydrogen
bond with Gln13 projecting from helix A of MA12 (position A2c)
(Fig. 6d). At the other end, Tyr110 on MA12, a conserved residue
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in all matured binders (Supplementary Table 3), inserts into a
pocket on IL-23 p19 deﬁned by the BC and AB loops and the
N-terminal part of helix D (Fig. 6e). Furthermore, we note that
this segment of the AB loop in the p19 subunit of IL-23 is
disordered in all currently available crystal structures of IL-23 (refs
22–24,45), suggesting that the interaction with the Alphabody
induces the observed conformation. Contrary to helices A and C
of MA12, helix B does not participate at all in the binding epitope
with p19 (Fig. 6). The glycine-rich linkers connecting the three
helices could not be visualized in the electron density maps and
were not included in the model. Importantly, comparison of the
variable positions in MA12 involved in the binding interface with
IL-23 with those of MB23, another well-performing Alphabody,
reveals strong sequence conservation levels (Fig. 6f and
Supplementary Table 3). Thus, such strong sequence conservation
patterns in residues involved in contacts with IL-23 and the very
similar binding proﬁles shared by the best binders (Table 1),
essentially warrant that all matured high-afﬁnity binders bind
using similar structural principles.
We were intrigued by persisting residual difference electron
density emanating from the Cd1 position of Trp319 in IL-23 p40
up to the last rounds of reﬁnement. Given previous reports that
IL-12, a cytokine related to IL-23, can be C-mannosylated via a
tryptophan residue46, we wondered whether this would also be
the case for IL-23. Indeed, mass spectrometry on tryptic peptides
of our recombinant human IL-23 conﬁrmed that Trp319 in the
p40 subunit of IL-23 is mannosylated (Supplementary Fig. 4a,b).
However, modelling of a C-linked mannose to Trp319 proved
challenging due to the likely structural heterogeneity of this
adduct47, prompting us to omit the sugar moiety from the ﬁnal
models.
Finally, we note that the engineered Cys60, located in the
middle of helix B of MA12 and all other afﬁnity-matured
Alphabodies (Supplementary Table 3), remains freely accessible
to solvent well away from the interaction epitope and is well
positioned for introducing potential post-translational chemical
modiﬁcations to improve bioavailability and modulate physico-
chemical properties. For example, the 40-kDa PEG-moiety
attached to the MB23 Alphabody in the in vivo study on mice
can be expected not to interfere with the binding, as also
evidenced by in vivo data.
Discussion
The growing need for therapeutics that can efﬁciently antagonize
biomedically relevant protein–protein interactions has stimulated
the expansion of the repertoire of novel and repurposed
protein scaffolds. Despite good progress in the development of
antibody-based48 and non-antibody scaffolds6 to serve as
therapeutic biologicals in the areas of cancer, autoimmune
diseases and inﬂammatory disorders1, the available approaches
are yet to reach their full potential, as many drug
discovery/development programmes are faced with high
attrition rates49.
Here we reported on the development of a novel protein
scaffold, termed the Alphabody, which emerged from a
combination of de novo design and experimental validation.
Alphabody sequences were found to fold as antiparallel triple-
stranded a-helical coiled-coil structures, thus adopting a
previously unknown fold. The core of the antiparallel coiled-coil
fold features tightly packed isoleucines at conventional heptad a-
and d-positions with a regular ‘knobs-into-holes’ conﬁguration,
wherein the a- and d-residues of the antiparallel B-helix form
core layers together with d- and a-residues, respectively, from the
two parallel helices A and C. This type of packing is similar in
conﬁguration, yet distinct at the atomic level, from the
leucine-stabilized antiparallel three-stranded ‘coiled serine’
structure36, and possesses exceptional thermostability. Thus,
such near-optimal core packing and the repetitive nature of the
constituting heptad repeats allow for a scalable scaffold that is
insensitive to multiple substitutions, thereby enabling the design
of generic libraries for phage display that can exploit the entire
scaffold surface, rather than the loop regions, as is the case for
most other scaffold proteins. More speciﬁcally, Alphabodies can
carry up to 25 variable positions that can be optimized for
binding and other properties. This offers important advantages in
the therapeutic targeting of protein–protein interfaces, an area of
increasing signiﬁcance in drug development. In addition, the
possibility to combine several tailor-made properties, including
optimization of loop regions, on such a robust scaffold
offers opportunities to develop Alphabodies that are minimally
immunogenic, paving the way for (pre)clinical development of
the scaffold. Current approaches to predict and assess the
immunogenicity of protein therapeutics range from
computational strategies to screening against human leukocyte
antigen class II molecules, cellular models employing CD4þ
T cells, as well as transgenic animal models including
immunodeﬁcient mice reconstituted with human hematopoietic
stem cells7,50,51.
Our Alphabody libraries were subdivided into structural
‘themes’, focusing on either the concave groove surface formed
by the A- and C-helices, or the convex B-helix surface. The
biopanning campaign against the present target, IL-23, using a
mixture of the libraries converged towards groove binders only.
Importantly, matured Alphabody variants were shown to potently
suppress IL-23-mediated inﬂammatory phenotypes in vitro, with
the best-performing Alphabodies reaching subnanomolar
Table 2 | Crystallographic data collection and reﬁnement
statistics.
Crystal form 1 Crystal form 2
Data collection
Space group P1211 P41212
Unit cell dimensions
a, b, c (Å) 56.96 56.74 100.07 57.85 57.85 366.48
a b g () 90, 99.73, 90 90, 90, 90
Resolution (Å) 41–1.74 (1.85–1.74) 57–3.4 (3.5–3.4)
Rmeas (%) 5.4 (63.6) 11.6 (92.1)
oI/s(I)4 13.7 (1.8) 20.7 (5.2)
Completeness (%) 97.9 (91.1) 99.85 (100.0)
Redundancy 3.4 (3.4) 22.3 (23.4)
Reﬁnement
Resolution (Å) 40–1.7 57–3.4
No. of reﬂections 213960 (32767) 212910 (9551)
Rwork/Rfree 0.17/0.22 (0.27/0.33) 0.26/0.29 (0.34/0.38)
No. of atoms*
Protein 4,295 4,060
Ligand/ion/glycan 35/2/61  / /60
Water 410 —
B-factors (Å2)*
Protein 38.7 116.3
Ligand/ion/glycan 62.9/39.7/34.4  / /104.6
Water 41.6 —
R.m.s.d.
Bond lengths (Å) 0.007 0.005
Bond angles () 1.04 1.1
r.m.s.d., root mean squared deviation.
Each of the reported data sets was obtained from one crystal.
*Hydrogens excluded.
Values in parentheses refer to the highest-resolution shell.
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afﬁnities in various binding assays (Table 1; Fig. 4). The observed
kinetic binding proﬁles of both the initial clones and the matured
Alphabodies are within ranges observed for high-afﬁnity protein–
protein interactions (konB105–106M 1 s 1 and koff values
B10 4–10 5 s 1) (Table 1). In this regard, it was surprising
to see that the gain in binding afﬁnity in matured Alphabodies
appeared to result primarily from improvements in the associa-
tion rate constants by about an order of magnitude (Table 1). In
combination with their favourable physicochemical properties,
such binding potencies promise to render Alphabodies as multi-
purpose anti-inﬂammatory agents for the treatment of inﬂam-
matory disorders such as rheumatoid arthritis, inﬂammatory
bowel disease and multiple sclerosis15. This was partly validated
in this study by the successful in vivo results obtained via
intradermal and intraperitoneal injection of MB23-PEG in mice.
Furthermore, the fact that the developed Alphabodies exclusively
target the p19 subunit of IL-23 and show no cross-reactivity with
IL-12, offers the opportunity to decouple therapeutic modulation
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of signalling pathways mediated by IL-23 from those mediated by
IL-12 (ref. 15).
The design principles employed to develop the Alphabody
scaffold and subsequent libraries were borne by our structural
data. Arguably one hallmark of the Alphabody platform is the
way it employs the surface deﬁned by two of the scaffold helices
to target a hitherto unexploited binding site on the p19 subunit of
human IL-23 (Figs 6 and 7). The binding mode observed in the
complex of MA12 with human IL-23 is strongly reminiscent of
the principles employed in the two-sided design of a de novo
binding pair52. In this binding mode, aromatic side chains with
amphipathic character, such as tryptophan and tyrosine, are
mutually contributed by the binding pair to mediate both
aromatic and H-bonded interactions. Interestingly, Alphabody
MA12 sequesters Trp156 on human IL-23 (Fig. 6), a residue
that has been proposed as a hotspot for the binding of cognate
IL-23R (ref. 24).
The potential to exploit the Alphabody scaffold to target
diverse binding epitopes via classical biopanning and selection
approaches and/or computational design is intrinsically large.
Computational approaches are steadily emerging but are still
lacking the robustness of experimental strategies based on
screening and selection. The a-helical nature of the Alphabody
scaffold, however, makes it particularly amenable to design
techniques such as the grafting of binding motifs from natural
a-helical ligands, at least in cases for which structural templates
are available. The present study also illustrates how initial drug
discovery can be accomplished by exploring different thematic
libraries. Subsequently, once a preferred type of binding surface
has been determined (for example, a groove, helix or a loop) and
initial binding sequences are available, the rigid a-helical nature
of the scaffold will essentially allow modelling of individual
sequences onto a scaffold template structure with reasonable
accuracy. In addition, the rigidity of the Alphabody helices may
provide an entropic advantage when the helical surfaces are
structurally compatible with the binding epitope. We envisage
that such design options will considerably facilitate the rational
design of focused libraries for further afﬁnity maturation. Finally,
having delineated a given critical binding region, the remainder of
the scaffold can be independently optimized for other purposes
such as solubility enhancement, biospeciﬁcity, labelling and
PEGylation.
Methods
Recombinant production of Alphabodies. The complementary DNA (cDNA) of
Alphabodies was cloned as N-terminally tagged decahistidine fusion proteins
into the pET16b-vector (Novagen). Recombinant production was performed
in transformed BL21(DE3)pLysS cells (Life Technologies), grown in Luria-Bertani
(LB) medium at 37 C. Expression was induced by adding 1mM isopropylthio-
b-galactoside at an OD600nm of 0.6 and expression was continued for 4 h
at 37 C. Cells were harvested by centrifugation and resuspended in 50mM Tris,
500mM NaCl pH 7.8 and frozen at  80 C. Cell lysis was performed by
thawing and sonication. 4-(2-aminoethyl) benzenesulfonyl ﬂuoride hydrochloride
(0.1mM) was added to the lysed cells, together with 10 mgml 1 DNAseI and
5mM MgCl2. The suspension was centrifuged for 20min at 40,000 g. Typically,
Alphabodies were puriﬁed from the soluble fraction, which was loaded on
a 5-ml IMAC HP Ni sepharose column (GE Healthcare) and eluted with an
imidazole gradient over 15 column volumes. Final polishing and desalting was
performed on a Superdex 75 size-exclusion column (GEHealthcare) equilibrated
in PBS.
Development of Alphabody libraries. Genes with position-speciﬁc randomiza-
tion (NNK) were designed wherein the Alphabody sequences were fused
N-terminally to the pIII protein of bacteriophage M13. These libraries were
ordered from GeneArt AG (Germany) and delivered as transformed E. coli cells
(strain ER2738, supE strain). The library sizes ranged from 1.0 to 1.7 108 unique
clones. Alphabody displayed on pIII of the phagemid was conﬁrmed by western
blot analysis using anti-pIII (MoBiTec GmbH) and amounted to about 10% of total
pIII protein.
Biopanning procedure. A biopanning campaign was set up using a mixture of
equal amounts of the three libraries scLib_AC11, scLib_AC7 and scLib C9.
A soluble panning format was applied, that is, phages were pre-incubated with the
target and subsequently captured on streptavidin beads. The preincubation was
performed during 1 h at room temperature (RT) on an end over end shaker, with
hIL-23 (Biolegend) bound to biotinylated anti-IL-23p40 antibody (Biolegend) in a
2:1 molar ratio in PBS supplemented with 2% skimmed milk. The capturing step
was performed using Dynabeads (50 ml). Beads were washed 10 times with 1ml of
0.1% Tween 20 in PBS. Elution was performed with 200 ml of buffer (100mM
glycine–HCl, pH 2), and the eluate was neutralized by adding 50 ml of 1M Tris pH
8.0. Five consecutive panning rounds were conducted wherein the hIL-23 target
concentration was decreased as of round 3 (rounds 1 and 2: 200 nM, rounds 3–5:
100, 10 and 1 nM, respectively). Phagemid was propagated as follows. Neutralized
phagemid solution was added to 1.75ml of LB. After taking out 50 ml for further
titration, the rest of the phagemid solution was added to 18ml of TG1 cells that had
already grown to the exponential phase (OD600 nm¼ 0.5). After 30min incubation
at 37 C, the solution was centrifuged and the pellet was resuspended in 250ml of
LB mediumþ ampicillinþ glucose. Overnight (O/N) incubation was performed at
37 C (180 r.p.m.).
Screening and competition ELISA. Phage ELISA was used to screen for positive
clones and to check which of them showed competition with the neutralizing
antibody B-Z23, as follows. Nunc ELISA plates were coated with 100 ml per
well neutravidin (10 mgml 1) in PBS for 1 h at RT. In the following steps, the plate
was washed 5 times with PBS, 0.05% Tween 20, between each incubation step.
The plate was blocked O/N at 4 C with 200 ml per well of PBS, 0.5% gelatin and
0.1% BSA. Biotinylated anti-human-p40 (100ml, 100 nM, Biolegend) in 0.1%
BSA–PBS was added for 1 h at RT. For the competition ELISA, 150 nM hIL-23
(Biolegend) was pre-incubated with 150 nM antibody B-Z23 (CellSciences) in 0.1%
BSA–PBS for 1 h at RT. For the screening ELISA, the same sample without B-Z23
antibody was used. Then, 66.6 ml of this sample (ﬁnal concentration 100 nM) and
33.3 ml of rescued phagemid supernatant was added to the plate for 2 h at RT.
Bound phagemid was detected with anti-M13-HRP (GE Healthcare) for 0.5 h
at RT followed by 3,30 ,5,50-tetramethylbenzidine (TMB) (Sigma) staining. The
colour reaction was stopped with 100 ml 0.5M H2SO4.
Phagemid rescue. TG1 cells, infected with selected phagemid, were titrated on an
agar plate (2TY, agar, ampicillin). Individual clones were picked from the agar
plate and cultured O/N in a microtiter plate containing 100 ml 2TY AG per
well53. One ml of each O/N culture was transferred to a microtiter plate containing
Alphabody
IL-23 IL-23 IL-23
Adnectin
mAB 7G10
p19 p19 p19
p40 p40 p40
Figure 7 | Comparison of binding modes of human IL-23 with antagonists. Comparison of structures for different IL-23:antagonist complexes:
Alphabody:IL-23 complex, adnectin:IL-23 complex (pdb code 3QWR)45 and 7G10 antibody:IL-23 complex (PDB code 3D85)22. The complexes are oriented
based on structural superpositions against the p19 subunit of human IL-23.
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100ml of 2TY, 0.1% glucose, 100mgml 1 ampicillin and 108 helper phage per
well and grown at 37 C for 2 h while shaking. Kanamycin/ampicillin (30ml) was
added to each well to a ﬁnal concentration of 100 and 30 mgml 1, respectively.
After O/N incubation at 30 C while shaking, plates were spun (611g for 20min),
and supernatant containing phagemid expressing Alphabody was used directly in
ELISA.
ELISA assays. Phage-coated ELISA. To screen for IL-23-positive clones, we
developed a phage-coated ELISA method. First, 100 ml anti-M13 at 5 mgml 1 in
PBS was coated O/N at 4 C (VWR, 27942001) onto a Nunc Maxisorp microtiter
plate (Thermo Scientiﬁc, 42404). Then the plate was blocked with 130 ml PBS, 0.1%
BSA, 0.5% gelatin for 1 h at RT. Between incubations, plates were washed with PBS
containing 0.05% Tween 20. After addition of 70 ml PBS with 0.1% BSA to the
washed wells, 30ml phagemid from a 96-well rescue of clonal phagemid was added.
Following an incubation of 1 h at RT and a washing step, 1 nM IL-23 (eBioscience,
34-8239-85) was added for 1 h at RT. Then after washing, 100 ml biotinylated anti-
p40 in PBS 0.1% BSA (Imtec Diagnostics, BE 505302) was added. For each clone,
the background (without IL-23) was measured as well. After washing, staining was
performed with 100ml streptavidin-HRP in PBS 0.1% BSA (Biolegend, 405210)
followed by a TMB reaction that was stopped with 0.5M H2SO4. The OD values
were measured at 450 nm (OD450). A clone was scored as positive when
ODtarget43ODbackground.
To measure the afﬁnities of the Alphabodies at the phagemid level, we
optimized the phage-coated ELISA as described above and incubated different
dilutions of target O/N at RT with the coated phagemid. Phagemid (30 ml in 70 ml
PBS, 0.1% BSA) was coated indirectly via anti-M13 as described above, and IL-23
was diluted in a concentration range from 10 to 0.0098 nM (1/5 dilutions) in PBS,
0.1% BSA, and 100 ml was added to the plate after washing away the non-bound
phagemid. In the phage-coated ELISA format, the phagemid with IL-23 incubation
was carried out O/N at RT. IL-23 binding was detected with biotinylated anti-p40
and streptavidin-HRP.
Standard and kinetic ELISA assays. Neutravidin (10 mgml 1 in PBS) was
coated onto a Nunc plate for 1 h at RT. Plates were washed 5 with PBSþ 0.05%
Tween 20 and blocked O/N with 0.1% BSAþ 0.5% gelatin at 4 C. Biotinylated
anti-p40 antibody (Imtec Diagnostics, 10 nM in PBSþ 0.1% BSA) was incubated
for 1 h at RT, followed by washing. Next, human IL-23 (eBioscience, 10 nM in
PBSþ 0.1% BSA) was incubated for 1 h at RT while shaking, followed by washing.
For the standard ELISA, ﬁvefold dilution series of Alphabodies in PBSþ 0.1% BSA
were incubated for 24 h while shaking (plates meanwhile covered with paraﬁlm),
followed by washing. For the kinetic ELISA, the same dilution series was added at
different time points (24, 3, 1 h, 15, 8 and 4min) before the washing step; wells not
yet ﬁlled with Alphabody were temporarily ﬁlled with PBSþ 0.1% BSA. Both types
of ELISA were developed with anti-penta-His-HRP (1/1,000 in PBSþ 0.1% BSA)
for 1 h at RT, while shaking. Further steps were as described for the phage-coated
ELISA.
Kinetic binding data in the context of kinetic ELISA assays were derived as
follows: ODs were divided by the maximum OD values to obtain the fraction of
bound IL-23 (vertical axis in Supplementary Fig. 3). Each full data set was ﬁtted
with only two parameters, KD and kon, to yield koff.
Mouse splenocyte assay. To assess the inhibitory capacity of the selected
Alphabodies in an in vitro assay, a mouse splenocyte assay was set up40. Human
IL-23 in the presence of IL-2 stimulates the production of IL-17 in murine
splenocytes at very low (picomolar) concentrations, which can be inhibited by co-
incubation of inhibitors against either p40 or p19. The IL-17 response (measured
using a Quantikine ELISA kit, R&D Systems) was determined in parallel for a
calibration experiment with increasing hIL-23 concentrations and for an inhibition
experiment using a ﬁxed (2.6 pM) IL-23 concentration and increasing Alphabody
concentrations (ﬁvefold dilutions in the range 0–1 mM). The inhibition constants KI
were determined by ﬁtting the data to a nonlinear equation describing the
relationship between OD values and total Alphabody concentrations. The
calibration and inhibition experiments were performed in fourfold and eightfold,
respectively, on the same ELISA plate (data were averaged).
DB cell assay. hIL-23 induces STAT3 phosphorylation upon engagement with
IL-23R at the surface of DB (human lymphoma) cells (DSMZ, Germany).
A calibration curve was established by determining the level of STAT3 phospho-
rylation in DB cells as a function of added human IL-23 within a concentration
range of 0.01–10 nM. To measure the inhibitory activity of the hIL-23-binding
Alphabodies, varying concentrations of Alphabodies (500–0.01 nM) were
pre-incubated with a ﬁxed concentration of hIL-23 (200 pM) and pre-incubated
samples were added to DB cells for 1 h, in parallel to the calibration curve
samples. Subsequently, DB cell lysates were prepared for STAT3 phosphorylation
measurement by sandwich ELISA (PathScan ELISA). Inhibition curves were ﬁtted
to derive inhibition constants KI of the tested Alphabodies.
Psoriasis animal model. To determine the ability of afﬁnity-matured Alphabodies
to antagonize IL-23-driven inﬂammation in vivo, a 40-kDa linear PEGgylated form
of variant MB23 (MB23-PEG) was tested in a mouse ‘ear model’42,43. Local ear skin
inﬂammation was induced by repeated intradermal administrations of human
IL-23 (1 mg) every other day within a period of 15 days into the right ear pinna of
20 male C57Bl/6J mice (Harlan Laboratories, Horst, Netherlands) that were 10
weeks old at the start of the experiment. The control group received intradermal
PBS injections under the same administration scheme. MB23-PEG was
administered by intradermal (10 mg; Group B) or intraperitoneal (40mg kg 1;
Group C) administrations on days  1, 0, 3, 6, 9, 12 and 15. Group A mice were
not administered MB23-PEG, but PBS instead as a vehicle control. Skin swelling
was measured by determining the ear skin thickness with a caliper on day 0 and
subsequently every other day until day 16. The animal studies were approved by
the Ethics Committee for Animal Protection under the jurisdiction of the regional
administrative authority of Karlsruhe, Germany.
Recombinant proteins for crystallographic studies. For large-scale production
cDNA for the MA12_B2fC Alphabody was cloned into the pET16b-vector
(Novagen) in frame with a N-terminal decahistidine tag. Recombinant production
was performed in transformed BL21(DE3)pLysS cells, grown in LB medium at
37 C. Expression was induced by adding 1mM isopropylthio-b-galactoside at an
OD600 nm of 0.7 and expression was continued for 4 h at 37 C. Washed inclusion
bodies were solubilized in 6M guanidine hydrochloride (GuHCl), loaded on a Ni
Sepharose column, washed with buffer devoid of GuHCl, and eluted with imida-
zole. Next, the desalted protein sample was incubated for 2 h at 37 C with mag-
netic trypsin beads to remove the N-terminal His-tag. The free cysteine of the
MA12_B2fC Alphabody was blocked for 15min by incubating with 5mM iodoa-
cetamide. Finally, as a polishing step the sample was injected on a Superdex 75
column equilibrated with 20mM HEPES, 150mM NaCl, pH 7.4.
Human IL-23 was produced by transient expression in mammalian cells23.
cDNAs corresponding to the human IL-23 subunits, p19 (residues 1–189) and p40
subunits (residues 1–328) were purchased from GeneArt and cloned into the pHL
expression vector54 between the EcoRI and KpnI sites. The p19 subunit was cloned
in frame with the C-terminal His-tag, while the p40 expression construct carried a
stop codon before the KpnI site. Both p19 and p40 cDNA sequences corresponded
to the reference sequences in the NCBI databank, NM_016584.2 and
NM_002187.2, respectively. However, the AAT codon for Asn248 in the p40
sequence was replaced with AAC to remove an EcoRI site. Large-scale expression
experiments in human embryonic kidney 293T (HEK-293T) cells were conducted
in roller bottles. HEK-293T cells grown in roller bottles were co-transfected with
the pHL-p19-His and pHL-p40 expression constructs in a 1:1 ratio, using
polyethyleneimine as transfection reagent. Expression was performed in serum-free
Dulbecco’s modiﬁed Eagle’s medium/F12 medium supplemented with 5 mM
kifunensine. Human IL-23 was puriﬁed from the conditioned medium by
immobilized metal-ion afﬁnity chromatography using Talon matrix (Clontech)
followed by SEC using a Superdex 200 column (GE Healthcare).
Crystal structure determination of the IL-23:MA12 complex. The IL-23:MA12
complex was formed by adding a molar excess of the MA12_B2fC Alphabody to
recombinant human IL-23 that had been partially deglycosylated O/N with
Endoglycosidase H (New England Biolabs). The complex was isolated from the
excess of Alphabody by SEC using a Superdex 200 column with 20mM HEPES,
150mM NaCl, pH 7.4 as running buffer, and concentrated by ultracentrifugation
to 6mgml 1. Nanolitre crystallization trials were set up at RT using a Mosquito
crystallization robot (TTP Labtech) against commercially available sparse matrix
screens (Hampton Research and Molecular Dimensions). Numerous hits were
obtained in the PEG/ION HT screen. Additional hits were found in various con-
ditions of the ProPlex HT and Crystal Screen HT screens.
Single crystals from optimized conditions were transferred to a drop of reservoir
solution with the use of a nylon loop mounted on a SPINE standard cryocap, and
cryoprotected with 20% PEG 400 before being ﬂash-frozen in liquid nitrogen.
Diffraction experiments were conducted on the X06SA and X06DA beamlines at
the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland). Data were
integrated and scaled using the XDS suite55. Crystals belonging to crystal form 1
were grown from 20.75% (w/v) PEG 3,350, 200mM Na2SO4. Crystals belonging to
crystal form 2 were grown from 20.75% (w/v) PEG 3,350, 200mM potassium
formate. The structure of the IL-23:MA12_B2fC complex was determined by
maximum-likelihood molecular replacement as implemented in the program suite
PHASER56, using the structure of human IL-23 (PDB entry 3DUH)24 as a search
model and structure-factors derived from X-ray diffraction data measured from
crystal form 1 crystals. Model (re)building was carried out manually using the
program COOT57. Crystallographic reﬁnement and structure validation were
carried out using PHENIX58.
Buried surface areas and analysis of interaction interfaces were calculated via
the PISA server59. Rendering of the structures as illustrated in Figs 3–5 and
Supplementary Figs 4 and 5a was carried out in PyMOL60.
ITC. For calorimetric measurements, recombinant human IL-23 and the
MA12_B2fC Alphabody were prepared by SEC in the same running buffer (20mM
Hepes, 150mM NaCl, pH 7.4). Protein concentrations were measured spectro-
photometrically at 280 nm using calculated theoretical extinction coefﬁcients, and
all solutions were extensively degassed before use. Experiments were carried out
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using a VP-ITC MicroCalorimeter (MicroCal, MA) at 30 C, and data were ana-
lysed using the Origin ITC analysis software package supplied by MicroCal.
Human IL-23 (4.9 mM in the microcalorimeter cell) was titrated with MA12
Alphabody (53.2 mM in the titration syringe). Titrations were preceded by an initial
injection of 3 ml, and were carried out using 5-ml injections applied 300 s apart,
under constant stirring. The thermal titration data were ﬁtted to the ‘one binding
site model’, and apparent molar reaction enthalpy (DH), apparent entropy (DS),
dissociation constant (KD) and stoichiometry of binding (N) were determined.
SPR. SPR experiments were carried out using a Biacore 3,000 instrument at 25 C
with HBS-EP pH 7.4 (GE Healthcare) as running buffer. Forty-three RU of
MA12_B2fC were immobilized on a CM5 chip by amine coupling. Recombinant
human IL-23 (eBioscience) was used as analyte at concentrations between 0.5 and
40 nM and kinetic data were collected at a ﬂow rate of 30 ml min 1. For each
sample, a 3-min association phase was followed by a 20-min dissociation phase.
The chip was regenerated between consecutive samples with 2 pulses of 30 s with
10mM glycine–HCl buffer pH 1.5. After double reference-subtraction, sensor-
grams were analysed using the BiaEvaluation software (version 4.1). Kinetic
parameters were ﬁtted to a 1:1 Langmuir model.
Mass spectrometry. Two ml of the same sample used in the crystallization
experiments was diluted in 50 ml of 50mM ammonium bicarbonate pH 7.5. The
sample was subsequently digested with trypsin (Porcine, sequencing grade, Pro-
mega, Madison, WI) O/N at 37 C using an enzyme to protein ratio 1:20. Formic
acid was added to a ﬁnal v/v concentration of 0.1% before the liquid chromato-
graphy mass spectrometry analysis. The digest was separated using an ultra per-
formance Nano Acquity system coupled to a Synapt G1 mass spectrometer
(Waters, Milford, MA). The peptides were separated on an HSS T3
(75 mm 250 mm, 1.8 mm particles) column (Waters) with a gradient of 3–40% of
buffer A (0.1% formic acid) and buffer B (100% acetonitrile with 0.1% formic acid).
The spectra were acquired in Liquid-chromatography mass spectrometry in ele-
vated energy mode (LCMSE) mode (alternating low and high collision energy) with
mass range from 125 to 2,000m/z using a collision energy ramp (10–40V)61. The
data were analysed using the Proteinlynx Global Server V2.5 platform (Waters)
against UniProt database using C-mannosylation as a variable modiﬁcation.
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